# US 2022/0033367 A1 · Prodrugs of 4-((1r, 3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-y)-1-,2,2-trimethylpiperazine and 4-((1r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1yl)-2,2-dimethyl-1 (methyl-d3)piperazine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033367 A1
- Document ID: US20220033367A1
- Status: Published application
- Kind: A1
- Application number: 17/297,717
- Filed: 2019-11-27
- Published: 2022-02-03
- Earliest claimed: 2018-12-03
- Assignees: H. Lundbeck A/S
- Applicants: H. Lundbeck A/S
- Inventors: MIkkel Fog Jacobsen; Morten Jørgensen
- Web page: https://patentgrep.com/patent/US20220033367A1

## CPC

- C07D 295/037: with quaternary ring nitrogen atoms
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine in the form of 2a and 2b, wherein X—is a counter ion, or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising prodrugs, or pharmaceutically acceptable salts thereof, of the invention.

## Claims

### Claim 1

A prodrug of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a or 1b or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d5)piperazine in the form of 2a and 2b
wherein X− is a counter ion selected from the group consisting of halide anion, optionally fluorinated C1-C10 sulfonate, and optionally fluorinated linear or branched C1-C11 carboxylate; and
wherein R is selected from the group consisting of linear or branched C1-C11 alkyl and C3-C10 cycloalkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The prodrug according to claim 1, wherein R is linear or branched C1-C11 alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The prodrug according to claim 1, wherein R is selected from the group consisting of methyl, tertbutyl, n-undecane and cyclohexylmethyl, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from hydrochloride acid, hydrobromide acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, saccharin and sulfonic acids.

### Claim 5 (depends on 1)

The prodrug according to claim 1 selected from the group consisting of (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)Application 1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d5)piperazin-1-ium, and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, each of which is combined with a counter ion selected from the group consisting of halide anion, optionally fluorinated C1-C10 sulfonate, and optionally fluorinated linear or branched C1-C11 carboxylate; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A pharmaceutical composition comprising any of the prodrugs of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim at position 7

-9. (canceled)

### Claim 10 (depends on 1)

A method for the treatment of a CNS disease, the method comprising administering a therapeutically effective amount of a compound according to claim 1 to a patient in need thereof.

### Claim 11 (depends on 1)

The prodrug according to claim 1, wherein R is C3-C10 cycloalkyl, or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid and benzenesulfonic acid.

### Claim 13 (depends on 2)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 2, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from hydrochloride acid, hydrobromide acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, saccharin and sulfonic acids.

### Claim 14 (depends on 3)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 3, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from hydrochloride acid, hydrobromide acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, saccharin and sulfonic acids.

### Claim 15 (depends on 11)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 11, wherein the pharmaceutically acceptable salt is selected from the group consisting of salts formed from hydrochloride acid, hydrobromide acid, phosphoric acid, nitrous acid, sulphuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, saccharin and sulfonic acids.

### Claim 16 (depends on 5)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 5, wherein the counter ion is selected from the group consisting of chloride, bromide and iodide.

### Claim 17 (depends on 5)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 5, wherein the counter ion is selected from the group consisting of mesylate, tosylate, trifluoromethanesulfonate, and nonafluorobutanesulfonate.

### Claim 18 (depends on 5)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 5, wherein the counter ion is trifluoroacetate.

### Claim 19 (depends on 1)

The prodrug, or a pharmaceutically acceptable salt thereof, according to claim 1, wherein the counter ion is selected from the group consisting of chloride, bromide, iodide, mesylate, tosylate, trifluoromethanesulfonate, nonafluorobutanesulfonate, and trifluoroacetate.
